175 related articles for article (PubMed ID: 21092078)
1. Potent inhibition of rhabdoid tumor cells by combination of flavopiridol and 4OH-tamoxifen.
Cimica V; Smith ME; Zhang Z; Mathur D; Mani S; Kalpana GV
BMC Cancer; 2010 Nov; 10():634. PubMed ID: 21092078
[TBL] [Abstract][Full Text] [Related]
2. Rhabdoid tumor growth is inhibited by flavopiridol.
Smith ME; Cimica V; Chinni S; Challagulla K; Mani S; Kalpana GV
Clin Cancer Res; 2008 Jan; 14(2):523-32. PubMed ID: 18223228
[TBL] [Abstract][Full Text] [Related]
3. Targeting cyclin D1, a downstream effector of INI1/hSNF5, in rhabdoid tumors.
Alarcon-Vargas D; Zhang Z; Agarwal B; Challagulla K; Mani S; Kalpana GV
Oncogene; 2006 Feb; 25(5):722-34. PubMed ID: 16302003
[TBL] [Abstract][Full Text] [Related]
4. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53.
Byrd JC; Shinn C; Waselenko JK; Fuchs EJ; Lehman TA; Nguyen PL; Flinn IW; Diehl LF; Sausville E; Grever MR
Blood; 1998 Nov; 92(10):3804-16. PubMed ID: 9808574
[TBL] [Abstract][Full Text] [Related]
5. The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner.
Ambrosini G; Seelman SL; Qin LX; Schwartz GK
Cancer Res; 2008 Apr; 68(7):2312-20. PubMed ID: 18381438
[TBL] [Abstract][Full Text] [Related]
6. Sequential combination therapy with flavopiridol and autocatalytic caspase-3 driven by amplified hTERT promoter synergistically suppresses human ovarian carcinoma growth in vitro and in mice.
Song Y; Xin X; Zhai X; Xia Z; Shen K
J Ovarian Res; 2014 Dec; 7():121. PubMed ID: 25528169
[TBL] [Abstract][Full Text] [Related]
7. Flavopiridol induces apoptosis in glioma cell lines independent of retinoblastoma and p53 tumor suppressor pathway alterations by a caspase-independent pathway.
Alonso M; Tamasdan C; Miller DC; Newcomb EW
Mol Cancer Ther; 2003 Feb; 2(2):139-50. PubMed ID: 12589031
[TBL] [Abstract][Full Text] [Related]
8. Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells.
Raju U; Nakata E; Mason KA; Ang KK; Milas L
Cancer Res; 2003 Jun; 63(12):3263-7. PubMed ID: 12810657
[TBL] [Abstract][Full Text] [Related]
9. Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.
Senderowicz AM
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S61-73. PubMed ID: 12819936
[TBL] [Abstract][Full Text] [Related]
10. [Synergism of antitumor effects on ovarian carcinoma using autocatalytic caspase-3 combined with flavopiridol].
Song Y; Shen K; Xu F
Zhonghua Fu Chan Ke Za Zhi; 2010 Oct; 45(10):781-6. PubMed ID: 21176562
[TBL] [Abstract][Full Text] [Related]
11. Therapeutically targeting cyclin D1 in primary tumors arising from loss of Ini1.
Smith ME; Cimica V; Chinni S; Jana S; Koba W; Yang Z; Fine E; Zagzag D; Montagna C; Kalpana GV
Proc Natl Acad Sci U S A; 2011 Jan; 108(1):319-24. PubMed ID: 21173237
[TBL] [Abstract][Full Text] [Related]
12. Retinoblastoma tumor suppressor gene expression determines the response to sequential flavopiridol and doxorubicin treatment in small-cell lung carcinoma.
Budak-Alpdogan T; Chen B; Warrier A; Medina DJ; Moore D; Bertino JR
Clin Cancer Res; 2009 Feb; 15(4):1232-40. PubMed ID: 19174488
[TBL] [Abstract][Full Text] [Related]
13. Flavopiridol potently induces small cell lung cancer apoptosis during S phase in a manner that involves early mitochondrial dysfunction.
Litz J; Carlson P; Warshamana-Greene GS; Grant S; Krystal GW
Clin Cancer Res; 2003 Oct; 9(12):4586-94. PubMed ID: 14555534
[TBL] [Abstract][Full Text] [Related]
14. Rapid induction of apoptosis by combination of flavopiridol and tumor necrosis factor (TNF)-alpha or TNF-related apoptosis-inducing ligand in human cancer cell lines.
Kim DM; Koo SY; Jeon K; Kim MH; Lee J; Hong CY; Jeong S
Cancer Res; 2003 Feb; 63(3):621-6. PubMed ID: 12566305
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors.
Rathkopf D; Dickson MA; Feldman DR; Carvajal RD; Shah MA; Wu N; Lefkowitz R; Gonen M; Cane LM; Dials HJ; Winkelmann JL; Bosl GJ; Schwartz GK
Clin Cancer Res; 2009 Dec; 15(23):7405-11. PubMed ID: 19934304
[TBL] [Abstract][Full Text] [Related]
16. Local cyclin-dependent kinase inhibition by flavopiridol inhibits coronary artery smooth muscle cell proliferation and migration: Implications for the applicability on drug-eluting stents to prevent neointima formation following vascular injury.
Jaschke B; Milz S; Vogeser M; Michaelis C; Vorpahl M; Schömig A; Kastrati A; Wessely R
FASEB J; 2004 Aug; 18(11):1285-7. PubMed ID: 15180955
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen and the PI3K Inhibitor: LY294002 Synergistically Induce Apoptosis and Cell Cycle Arrest in Breast Cancer MCF-7 Cells.
Abdallah ME; El-Readi MZ; Althubiti MA; Almaimani RA; Ismail AM; Idris S; Refaat B; Almalki WH; Babakr AT; Mukhtar MH; Abdalla AN; Idris OF
Molecules; 2020 Jul; 25(15):. PubMed ID: 32722075
[TBL] [Abstract][Full Text] [Related]
18. Cyclin-dependent kinase inhibitor, flavopiridol, induces apoptosis and inhibits tumor growth in drug-resistant osteosarcoma and Ewing's family tumor cells.
Li Y; Tanaka K; Li X; Okada T; Nakamura T; Takasaki M; Yamamoto S; Oda Y; Tsuneyoshi M; Iwamoto Y
Int J Cancer; 2007 Sep; 121(6):1212-8. PubMed ID: 17520676
[TBL] [Abstract][Full Text] [Related]
19. A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol.
Dickson MA; Shah MA; Rathkopf D; Tse A; Carvajal RD; Wu N; Lefkowitz RA; Gonen M; Cane LM; Dials HJ; Schwartz GK
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1113-21. PubMed ID: 20953860
[TBL] [Abstract][Full Text] [Related]
20. The effect of the cyclin-dependent kinase inhibitor flavopiridol on anaplastic large cell lymphoma cells and relationship with NPM-ALK kinase expression and activity.
Bonvini P; Zorzi E; Mussolin L; Monaco G; Pigazzi M; Basso G; Rosolen A
Haematologica; 2009 Jul; 94(7):944-55. PubMed ID: 19535344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
